Elsevier and Iktos Partner to Deliver an AI-Driven Synthetic Chemistry Platform for Drug Discovery
Combining the world's largest chemistry database, Reaxys from Elsevier, with cutting-edge AI from Iktos, the advanced platform will enable pharmaceutical companies to identify preclinical drug candidates faster
- The partnership will strengthen Elsevier's flagship chemistry solution, Reaxys , by combining the company's high-quality chemistry data with synthetic planning AI technologies developed by Iktos to accelerate chemistry research for pharmaceutical companies.
- We are delighted to partner with Iktos to bring the valued industry insights that Reaxys offers powered by artificial intelligence, which will help reshape the landscape of small molecule discovery."
- Yann Gaston-Mathé, CEO, Iktos said: "Data is the foundation of AI, and we are very excited to partner with Elsevier.
- The new predictive retrosynthesis and synthetic accessibility tools are based on Iktos' proprietary retrosynthetic technology and trained on Reaxys' reaction database.